<DOC>
	<DOCNO>NCT02283489</DOCNO>
	<brief_summary>This study investigate efficacy safety recombinant human endostatin adenovirus combine chemotherapy advanced head neck malignant tumor .</brief_summary>
	<brief_title>Recombinant Human Endostatin Adenovirus Combined With Chemotherapy Advanced Head Neck Malignant Tumors</brief_title>
	<detailed_description>Head neck cancer one common malignant tumor China , account 19.9 % 30.2 % malignant tumor country . Approximately 60 % 70 % patient stage III IV disease time diagnosis , 5-year overall survival 30 % . The local recurrence rate range 50 % 60 % . The 5-year overall survival patient treat multidisciplinary treatment , common treatment method include surgery , chemotherapy , radiotherapy , biotherapy , recently increase 5 % . Further improvement treatment effect head neck cancer require . Endostatin , endogenous angiogenesis inhibitor C-terminal fragment collagen XVIII , effectively inhibit tumor angiogenesis specific inhibition neovascular endothelial cell [ 7 , 8 ] . Its characteristic antitumor effect dose-dependent , require continuous high protein activity . Transportation recombinant gene adenovirus vector body lead continuous expression high level endogenous secretory protein , resolve limitation foreign protein infusion . Previous study show antitumor activity recombinant human endostatin adenovirus higher recombinant human endostatin protein . EDS01 , antitumor gene therapy product us recombine adenovirus type 5 vector human endostatin gene , may term recombinant adenovirus-recombined human endostatin gene . Intratumor injection EDS01 reportedly result transportation human endostatin gene tumor cell adenovirus infection , lead expression endostatin protein . Expression protein inhibits neovascular endothelial cell , neovascularization , tumor growth metastasis . Both vivo vitro experiment show EDS01 significantly inhibit growth neovascular endothelial cell tumor growth nude mouse xenograft model laryngocarcinoma nasopharyngeal carcinoma . A phase I clinical trial ( No . treatment effect ) conduct West China Hospital Sichuan University enrol patient superficial advanced head neck cancer lesion . The patient underwent injection different dos EDS01 , investigator perform preliminary evaluation maximally tolerate dose adverse event . The study show , whether administer dose escalation multiple dos , EDS01 well tolerate without dose-limiting toxicity maximum tolerate dose . The main side effect fever injection site pain flu-like symptom . A small amount EDS01 ( 1/10 000 000 ) absorb bloodstream . A thimbleful ( 1/100 000 000 1/10 000 000 000 ) excrete urine feces nontoxic environment . The target lesion exhibit treatment response . According result phase I trial , 5.0 × 1011 1.0 × 1012 virus particle ( VP ) EDS01 show adequate safety treatment response . Therefore , subsequent phase II clinical trial , optimal two dos determine . The treatment effect safety protocol head neck cancer also investigate . In summary , study initially explore efficacy safety recombinant human endostatin adenovirus combine chemotherapy advanced head neck malignant tumor . In experimental group , target lesion define injected EDS01 . In control group , target lesion define select inception .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Advanced head neck cancer unsuitable surgery radiotherapy ( include head neck squamous carcinoma nasopharyngeal carcinoma , 30 % ) Cytological and/or histopathologic diagnosis Target lesion treat intratumor injection Lesions measure image diameter ≥2 cm ( RECIST1.1 ) No chemotherapy , radiotherapy , biotherapy administer past 4 week Age 18 70 year Life expectation ≥12 week ECOG performance status 0 2 Laboratory examination perform ≤7 day enrollment follow result : absolute neutrophil count ≥1.5 × 109 L−1 , platelet count ≥80 × 109/L , total bilirubin level ≤2 mg/dL , AST ALT level ≤2 time upper limit reference range , coagulation parameter ≤1.5 time upper limit reference range Voluntary participation write informed consent Allergy EDS01 Nerves vessel pass target lesion allow injection EDS01 lesion Simultaneous radiation target lesion Cancer recurrence within 6 month treat paclitaxel Severe coagulation dysfunction bleed tendency Serious medical disease , myocardial infraction past 3 month , acute infection Currently pregnant lactate Any condition investigator regard unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Recombinant Human Endostatin Adenovirus</keyword>
	<keyword>Head Neck Malignant Tumor</keyword>
	<keyword>clinical trial</keyword>
	<keyword>randomize</keyword>
	<keyword>Endostatin</keyword>
	<keyword>gene therapy</keyword>
</DOC>